Clearmind Medicine and SciSparc Publish International Patent Application for Obesity Treatment

Clearmind Medicine Inc. and SciSparc Ltd. have published an international patent application under the Patent Cooperation Treaty (PCT) for a combination therapy of Clearmind's MEAI and SciSparc's Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity. The therapy aims to address high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels. The patent application was filed as part of their ongoing collaboration.

Clearmind Medicine Inc. (CMND) and SciSparc Ltd. (SPRC) have published an international patent application under the Patent Cooperation Treaty (PCT) for a combination therapy aimed at treating metabolic syndrome and obesity. The patent application, filed as part of their ongoing collaboration, covers a unique combination of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA).

Metabolic syndrome, characterized by conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels, affects up to one-third of U.S. adults and significantly increases the risk of heart disease, stroke, obesity, and type 2 diabetes [2]. This novel combination therapy leverages PEA's anti-inflammatory and neuroprotective properties alongside MEAI's unique pharmacological profile to offer potential safe and effective treatment for these widespread health challenges.

The patent application, published under the European Patent Office, represents one of 13 patent families filed across multiple jurisdictions, including the US, Europe, and China [3]. The collaboration between Clearmind and SciSparc focuses on developing innovative therapies that combine neuroplastic molecules with N-acylethanolamines, including PEA, to address mental health disorders, addictions, and various metabolic conditions [2].

Clearmind Medicine Inc., a clinical-stage psychedelic pharmaceutical biotech company, is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder [1]. SciSparc Ltd., a specialty clinical-stage pharmaceutical company, focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals [2].

The publication of this international PCT patent application marks a significant milestone in the Clearmind-SciSparc collaboration. However, investors should understand the distinction between patent publication and patent grant. The PCT process typically serves as a preliminary step before entering national phases where actual patents may be granted [3].

The science behind the combination is intriguing, with PEA's anti-inflammatory properties paired with MEAI's unique pharmacological profile potentially addressing multiple aspects of metabolic syndrome simultaneously. However, the company remains in clinical-stage development, meaning significant regulatory hurdles remain before commercialization [3].

References:
[1] Reuters. (2025). Clearmind Medicine receives IRB approval for phase 1/2A clinical trial for alcohol use disorder. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_TUA8DXFL1:0-clearmind-medicine-receives-irb-approval-for-phase-1-2a-clinical-trial-for-alcohol-use-disorder/
[2] SciSparc Ltd. (2025). SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High-Blood Sugar. Retrieved from https://www.globenewswire.com/news-release/2025/08/07/3129137/0/en/SciSparc-Clearmind-Collaboration-Leads-to-Publication-of-International-Patent-Application-for-Novel-Combination-Therapy-Targeting-Obesity-and-High-Blood-Sugar.html
[3] Stock Titan. (2025). SciSparc-Clearmind Collaboration Leads to Publication of SP4BPLNLV0HE. Retrieved from https://www.stocktitan.net/news/SPRC/sci-sparc-clearmind-collaboration-leads-to-publication-of-sp4bplnlv0he.html